32
Participants
Start Date
March 20, 2019
Primary Completion Date
November 18, 2019
Study Completion Date
December 18, 2019
inodiftagene vixteplasmid
"BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks"
Weill Cornell Medical College - NY Presbyterian Hospital, New York
Montefiore Medical Center, The Bronx
Albany Medical College, Albany
SUNY Upstate Medical University, Syracuse
MidLantic Urology, Bala-Cynwyd
The Hospital of the University of Pennsylvania, Philadelphia
Johns Hopkins Medical Institution, Baltimore
Virginia Urology, Richmond
Urology of Virginia, Virginia Beach
West Virginia University Cancer Institute, Morgantown
Alliance Urology Specialists, PA, Greensboro
UNC Chapel Hill Hospital, Urology Clinic, Chapel Hill
Duke University, Durham
Carolina Urology Partners, PLLC, Huntersville
Medical University South Carolina, Charleston
Regional Urology, Greenville
Emory University, Atlanta
Mayo Clinic Florida, Jacksonville
University of Florida Health Jacksonville, Shands Hospital, Jacksonville
Urology Associates, P.C., Nashville
University of Toledo, Dept. of Urology and Kidney Transplant, Toledo
Michigan Institute of Urology, PC, Troy
Spectrum Health Medical Group, Grand Rapids
Mayo Clinic, Rochester
University of Illinois Hospital and Health Systems (Outpatient Care Center), Chicago
Saint Louis University, St Louis
Washington University, St Louis
The University of Kansas Cancer Center, Westwood
Wichita Urology Group, Wichita
Tulane University School of Medicine, New Orleans
Ochsner Clinical Foundation, New Orleans
Arkansas Urology, Little Rock
University of Oklahoma Health Sciences Center, Oklahoma City
University of Texas Southwestern Medical Center, Dallas
Baylor College of Medicine Medical Center, Houston
The Methodist Hospital d/b/a Houston Methodist Hospital, Houston
The University of Texas MD Anderson Cancer Center, Houston
The Urology Center of Colorado, Denver
Idaho Urologic Institute, PA, Meridian
North Idaho Urology, Coeur d'Alene
Mayo Clinic Arizona, Phoenix
Banner MD Anderson Cancer Center, Gilbert
Urological Associates of Southern Arizona, Tucson
American Institute of Research, Los Angeles
UC Davis Medical Center, Sacramento
Alaska Urological Institute, Anchorage
New Jersey Urology, LLC, Belleville
MD Anderson Cancer Center at Cooper, Voorhees Township
Lead Sponsor
Anchiano Therapeutics Israel Ltd.
INDUSTRY